Txcell SA. TxCell SA is a France-based biotechnology company. It is engaged in the development of therapies to cure inflammatory and autoimmune diseases. The Company conducts medical research in anti-inflammatory immunotherapy. TxCell SA's technology is based on Tr1 T-regulatory cells which enable the regulation of the immune system. The Company's strategy aims at re-establishing this immunologic equilibrium by bringing regulatory T cells to the body. TxCell SA produces products which are used to treat Inflammatory Bowel Disease, primarily treatment resistant Crohns Disease (OvaSave), Inflammatory Joint Diseases, initially treatment resistant Rheumatoid Arthritis (TX-RAD) and Neurological Diseases, as well as targeting Multiple Sclerosis (TX-MSD).
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.